31 July 2017 - Cost regulators for NHS treatments in England and Wales are standing by their position that Orexigen’s weight loss pill Mysimba can not be recommended as a cost-effective treatment option.

The National Institute for Health and Care Excellence has published a final appraisal determination not recommending use of Mysimba (naltrexone/bupropion) as an adjunct to a reduced-calorie diet and increased physical activity for the management of weight in adult patients meeting certain criteria.

“Clinical trial evidence shows that naltrexone-bupropion with lifestyle measures is more effective than lifestyle measures alone, but its long-term effectiveness is unknown,” the Institute said.

Read Pharma Times article